Cargando…

Improvement of dysphagia in a child affected by Pompe disease treated with enzyme replacement therapy

AIM: Dysphagia is a known complication in Pompe Disease (PD), a severe metabolic myopathy due to alpha-glucosidase deficiency. Enzyme replacement therapy (ERT) with alglucosidase alfa is the only approved therapy for PD. Presently no data are available on the effects of ERT on dysphagia in PD patien...

Descripción completa

Detalles Bibliográficos
Autores principales:	Fecarotta, Simona, Ascione, Serena, Montefusco, Giuseppe, Della Casa, Roberto, Villari, Paola, Romano, Alfonso, Del Giudice, Ennio, Andria, Generoso, Parenti, Giancarlo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2013
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3667015/ https://www.ncbi.nlm.nih.gov/pubmed/23668440 http://dx.doi.org/10.1186/1824-7288-39-30

Ejemplares similares

S1.2 The pediatrician and the early onset Pompe disease
por: Fecarotta, Simona, et al.
Publicado: (2011)

S2.2 Enzyme replacement therapy in the infantile-onset Pompe disease
por: Parenti, Giancarlo, et al.
Publicado: (2011)

The Pharmacological Chaperone N-butyldeoxynojirimycin Enhances Enzyme Replacement Therapy in Pompe Disease Fibroblasts
por: Porto, Caterina, et al.
Publicado: (2009)

Correction of oxidative stress enhances enzyme replacement therapy in Pompe disease
por: Tarallo, Antonietta, et al.
Publicado: (2021)

Immune responses to alglucosidase in infantile Pompe disease: recommendations from an Italian pediatric expert panel
por: Gragnaniello, Vincenza, et al.
Publicado: (2022)

New treatments for the mucopolysaccharidoses: from pathophysiology to therapy
por: Fecarotta, Simona, et al.
Publicado: (2018)

Abnormal mannose-6-phosphate receptor trafficking impairs recombinant alpha-glucosidase uptake in Pompe disease fibroblasts
por: Cardone, Monica, et al.
Publicado: (2008)

Involvement of endocrine system in a patient affected by Glycogen storage disease 1b: speculation on the role of autoimmunity
por: Melis, Daniela, et al.
Publicado: (2014)

Enzyme replacement therapy (ERT) in pompe disease
por: Fiumara, Agata
Publicado: (2014)

Long term follow-up to evaluate the efficacy of miglustat treatment in Italian patients with Niemann-Pick disease type C
por: Fecarotta, Simona, et al.
Publicado: (2015)

Long term clinical history of an Italian cohort of infantile onset Pompe disease treated with enzyme replacement therapy
por: Parini, Rossella, et al.
Publicado: (2018)

Enzyme replacement therapy and fatigue in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Glycogen storage disease type Ia (GSDIa) but not Glycogen storage disease type Ib (GSDIb) is associated to an increased risk of metabolic syndrome: possible role of microsomal glucose 6-phosphate accumulation
por: Melis, Daniela, et al.
Publicado: (2015)

Long-term follow-up of patients with phenylketonuria treated with tetrahydrobiopterin: a seven years experience
por: Scala, Iris, et al.
Publicado: (2015)

Impact of enzyme replacement therapy on survival in adults with Pompe disease
por: Güngör, Deniz, et al.
Publicado: (2013)

Enzyme replacement therapy and antibodies in late-onset Pompe disease
por: Schneider, I., et al.
Publicado: (2014)

Teaching tolerance: New approaches to enzyme replacement therapy for Pompe disease
por: Cousens, Leslie P., et al.
Publicado: (2012)

Enzyme Replacement Therapy Can Reverse Pathogenic Cascade in Pompe Disease
por: Meena, Naresh Kumar, et al.
Publicado: (2020)

The impact of interrupting enzyme replacement therapy in late-onset Pompe disease
por: Wenninger, Stephan, et al.
Publicado: (2021)

Aortopathies in mouse models of Pompe, Fabry and Mucopolysaccharidosis IIIB lysosomal storage diseases
por: Belfiore, Maria Paola, et al.
Publicado: (2020)

Respiratory muscle training with enzyme replacement therapy improves muscle strength in late - onset Pompe disease
por: Mitja, Jevnikar, et al.
Publicado: (2015)

Enzyme replacement therapy reduces the risk for wheelchair dependency in adult Pompe patients
por: van der Meijden, Jan C., et al.
Publicado: (2018)

Albuterol as an adjunctive treatment to enzyme replacement therapy in infantile-onset Pompe disease()
por: Chien, Yin-Hsiu, et al.
Publicado: (2017)

Standardized nursing management of enzyme replacement therapy for late-onset Pompe disease
por: Tang, Shan, et al.
Publicado: (2021)

Improved Enzyme Replacement Therapy with Cipaglucosidase Alfa/Miglustat in Infantile Pompe Disease
por: Fiege, Lina, et al.
Publicado: (2023)

Facial-muscle weakness, speech disorders and dysphagia are common in patients with classic infantile Pompe disease treated with enzyme therapy
por: van Gelder, C. M., et al.
Publicado: (2011)

Pathogenesis of Mucopolysaccharidoses, an Update
por: Fecarotta, Simona, et al.
Publicado: (2020)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in adult patients with Pompe disease
por: Kanters, Tim A., et al.
Publicado: (2017)

Considerations for evaluating the effectiveness and long-term outcome of enzyme replacement therapy in Pompe disease
por: Cheon, Chong Kun
Publicado: (2019)

Hearing characteristics of infantile-onset Pompe disease after early enzyme-replacement therapy
por: Hsueh, Chien-Yu, et al.
Publicado: (2021)

Respiratory manifestations in patients with inherited metabolic diseases
por: Santamaria, Francesca, et al.
Publicado: (2013)

Ensuring continuity of care for children with inherited metabolic diseases at the time of COVID-19: the experience of a metabolic unit in Italy
por: Brunetti-Pierri, Nicola, et al.
Publicado: (2020)

Survival and associated factors in 268 adults with Pompe disease prior to treatment with enzyme replacement therapy
por: Güngör, Deniz, et al.
Publicado: (2011)

Cost-effectiveness of enzyme replacement therapy with alglucosidase alfa in classic-infantile patients with Pompe disease
por: Kanters, Tim A, et al.
Publicado: (2014)

Skeletal muscle pathology of infantile Pompe disease during long-term enzyme replacement therapy
por: Prater, Sean N, et al.
Publicado: (2013)

Comparative impact of AAV and enzyme replacement therapy on respiratory and cardiac function in adult Pompe mice
por: Falk, Darin J, et al.
Publicado: (2015)

Muscle Proteomic Profile before and after Enzyme Replacement Therapy in Late-Onset Pompe Disease
por: Moriggi, Manuela, et al.
Publicado: (2021)

A Systematic Review and Meta-Analysis of Enzyme Replacement Therapy in Late-Onset Pompe Disease
por: Dornelles, Alícia Dorneles, et al.
Publicado: (2021)

Home-based enzyme replacement therapy in children and adults with Pompe disease; a prospective study
por: Ditters, Imke A. M., et al.
Publicado: (2023)

Multicentric Retrospective Evaluation of Five Classic Infantile Pompe Disease Subjects Under Enzyme Replacement Therapy With Early Infratentorial Involvement
por: Paoletti, Matteo, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_qli96rs0fcsqea481vh2v87tnk